- IXICO, the brain health company, has been selected as a partner within The European Prevention of Alzheimer's dementia Initiative (EPAD), a novel collaboration between academic and private sectors to test innovative treatments for the secondary prevention of Alzheimer's dementia.

The 5-year programme is part of the Innovative Medicines Initiative (IMI), a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, (EFPIA). EPAD will establish a European-wide register of 24,000 participants, of which 1,500 will be invited to participate in trials to test new treatments for prevention of Alzheimer's dementia.

As part of this programme, IXICO will provide its TrialTracker platform to collect and manage imaging data in combination with its Assessa medical device to identify subjects who are most likely to benefit from treatment.

Story provided by